UnitedHealth enters its October 13 Q3 2026 earnings release with an 82.5% market-implied probability of beating consensus, driven by its recent streak of sizable positive surprises and an upgraded full-year outlook. In Q2 the company posted adjusted EPS of $6.38 against a $4.94–$5.22 consensus, a roughly 29% beat, while revenue reached $112.03 billion; management subsequently lifted 2026 adjusted EPS guidance to $19.50–$20.00 on stronger Medicare Advantage margins above 3% and a milder-than-expected membership decline of 1.1 million. Analysts currently project Q3 EPS near $4.12 with revenue around $111 billion, supported by continued medical-care-ratio improvement and Optum segment momentum. Traders price in the established pattern of outperformance ahead of the report.